The Ervebo vaccine has proven safe and effective against the common Zaire strain of the Ebola virus, with early data suggesting it may also protect against the rarer Bundibugyo strain, potentially leading to public availability in DR Congo.

Scientists have developed an experimental vaccine that successfully protected mice against three species of Ebola, including the Bundibugyo strain. New studies reveal the Bundibugyo strain is less lethal than the Zaire strain, killing 30% to 40% of infected people, while the vaccine still requires human testing.